DELFI Fragmentomics Supports Early Cancer Detection
We are creating next-generation liquid biopsy tests fueled by breakthroughs in genomics and machine learning.
Unlocking a Vast Trove of Diagnostic Data
Our unique fragmentomics technology isn’t limited to the small number of mutations or alterations detected by other liquid biopsy methods. We see a bigger picture.
Innovative, Advanced Machine Learning Platform
DELFI’s advanced machine learning, fragmentomics technology derives its analytical power by comparing cell-free DNA patterns against populations with and without cancer. The technology has demonstrated the ability to use millions of data points to identify the presence of cancer.
High Performance Methods
By examining cell-free DNA fragments across the genome, DELFI’s machine learning platform, supporting early cancer detection, analyzes orders of magnitude more data on the presence or absence of cancer than possible with conventional technologies that look for limited changes in DNA sequences.
A Growing Body of Evidence
First published in Nature in 2019, DELFI’s methods continue to demonstrate the potential of using this technology to develop high-performing, accessible liquid biopsy tests.
FRAGMENTOMICS studies the physical properties of circulating cell-free DNA fragments. DNA is packaged abnormally in cancer cells, resulting in abnormal fragment patterns when cancer cells die and release their DNA into the bloodstream. Cell-free DNA fragments in the blood can indicate the presence of cancer and suggest its likely location in the body.